Shared Medical Decision on Endocrine Drugs in women with breast cancer

Agreement: 
I Agree
Body: 

Dear Edito

In our routine outpatient clinic for breast cancer endocrine therapy, the majority of patients come with prescription requests of SERMs or AIs for their 5 to10 years of endocrine therapy. Some patients will complain of drug side effects, and the finger joints stiffness in the morning is the most common side effect. There is currently no effective way to handle the finger joint stiffness, which is usually not severe. Hence the time pressured doctor will just prescribe, without conversation with the patients about other medicines and comorbidities in the busy clinical settings. The prescription will be signed without adequate scrutiny.

Some patients will consult on the cessation of endocrine drugs. If the doctors advise the patients to discontinue endocrine drugs, most patients will show worry about breast cancer recurrence and/or metastasis without taking pills. Hence time-consuming shared medical decision (SMD) is warranted, which is not actionable in our busy outpatient clinical for breast cancer endocrine therapy. Without adequate SMD, the patients are inclined to continue taking their endocrine drugs. The problem in breast cancer endocrine therapy needs to be fully considered.

No competing Interests: 
Yes
The following competing Interests: 
Electronic Publication Date: 
Thursday, November 16, 2023 – 07:50
Workflow State: 
Released
Full Title: 

Shared Medical Decision on Endocrine Drugs in women with breast cancer

Check this box if you would like your letter to appear anonymously:: 
Last Name: 
Xu
First name and middle initial: 
Yali
Address: 
ShuaiFuYuan Hutong NO.1, Dongcheng District, Beijing,China
Occupation: 
researcher
Affiliation: 
Peking Union Medical College Hospital
BMJ: Additional Article Info: 
Rapid response

This post was originally published on this site

Leave a Reply

error: Content is protected !!
Open chat
WhatsApp Now